Aneuploidy, TP53 mutation, and amplification of MYC correlate with increased intratumor heterogeneity and poor prognosis of breast cancer patients
Sign Up to like & getrecommendations! Published in 2018 at "Genes"
DOI: 10.1002/gcc.22515
Abstract: The clinical course of breast cancer varies from one patient to another. Currently, the choice of therapy relies on clinical parameters and histological and molecular tumor features. Alas, these markers are informative in only a… read more here.
Keywords: cancer; aneuploid tumors; intratumor heterogeneity; breast cancer ... See more keywords